Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) chief executive Clarissa Sowemimo-Coker speaks to Thomas Warner from Proactive London after announcing that the company has begun phase I clinical trials for its lead drug candidate to treat .
With the first human doses being administered of OCT461201, researchers will assess the pain relief treatment's safety, tolerability, and pharmacokinetic profile (how it interacts with the body).
Sowemimo-Coker says it is "so important to have that significant milestone of finally getting that first dose into a healthy volunteer, so we can officially say we're on the way and looking forward to getting those results over time."
The trial holds promise for patients suffering from chemotherapy-induced peripheral neuropathy (CIPN), a condition affecting 60% of chemotherapy recipients, causing severe pain and sensitivity in extremities.
Sowemimo-Coker also highlights the recent addition to the team of Dr. Farquhar Smith, who runs the only CIPN clinic in the UK at the Royal Marsden.